Selected article for: "cell target and virus cell"

Author: Hsu, Shih-Hsien; Yeh, Ming-Lun; Wang, Shen-Nien
Title: New Insights in Recurrent HCV Infection after Liver Transplantation
  • Document date: 2013_4_23
  • ID: 0hbeso65_43
    Snippet: Interfering with HCV entry into the hepatocytes holds great promises for the development of novel drugs. Several potential targets are suggested: (1) blocking virus-target cell interaction during attachment and binding; (2) interfering with postbinding events and (3) interfering with viral fusion. Various modalities may be adopted as HCV entry inhibitors: neutralizing antibodies for HCV envelope glycoproteins, blocking antibodies specific for hos.....
    Document: Interfering with HCV entry into the hepatocytes holds great promises for the development of novel drugs. Several potential targets are suggested: (1) blocking virus-target cell interaction during attachment and binding; (2) interfering with postbinding events and (3) interfering with viral fusion. Various modalities may be adopted as HCV entry inhibitors: neutralizing antibodies for HCV envelope glycoproteins, blocking antibodies specific for host factors, and small molecular compounds against host factors or viral proteins.

    Search related documents:
    Co phrase search for related documents
    • binding attachment and entry inhibitor: 1, 2
    • binding attachment and envelope glycoprotein: 1
    • binding attachment and HCV entry: 1
    • binding attachment and host factor: 1, 2, 3
    • binding attachment and molecular compound: 1
    • binding attachment and neutralize antibody: 1
    • binding attachment and novel drug: 1, 2
    • binding attachment and novel drug development: 1
    • cell interaction and entry inhibitor: 1, 2, 3, 4
    • cell interaction and envelope glycoprotein: 1, 2, 3, 4, 5
    • cell interaction and great promise: 1
    • cell interaction and HCV entry: 1, 2
    • cell interaction and host factor: 1, 2, 3, 4, 5, 6, 7
    • cell interaction and molecular compound: 1
    • cell interaction and neutralize antibody: 1
    • cell interaction and novel drug: 1, 2, 3, 4
    • cell interaction and novel drug development: 1, 2
    • entry inhibitor and envelope glycoprotein: 1, 2, 3
    • entry inhibitor and HCV entry: 1, 2, 3